Diagnosis and treatment of liver metastases of parathyroid carcinoma

Chaoyun Su, Junwei Zhang, Huayu Yang, Yiyao Xu, Xin LüFrontiers in Endocrinology 2022 · DOI

Abstract

Parathyroid carcinoma (PC) is a rare malignant tumor prone to recurrence and metastasis, necessitating routine postoperative reviews. Abnormally elevated parathyroid hormone (PTH) and serum calcium levels are critical indicators of recurrence or metastasis. While enhanced CT and MRI provide valuable diagnostic support for liver metastases, the utility of [18F]FDG-PET-CT, [18F]FCH-PET-CT, or [11C]choline-PET-CT requires further investigation. Interventions such as resection of liver metastases, segmental hepatectomy, or radiofrequency ablation (RFA) can significantly improve patient symptoms and manage hypercalcemia.

Introduction

Parathyroid carcinoma (PC) is an exceptionally rare malignancy, accounting for less than 1% of primary hyperparathyroidism cases. Despite its slow growth, it is a relentless endocrine tumor. While the lungs are the most common site for distant spread, the liver is the second most frequent target for metastasis. Currently, no clinical guidelines exist for managing liver metastases in PC.

The management of PC liver metastases faces two primary challenges: diagnostic ambiguity due to the lack of standardized protocols and treatment uncertainty regarding the choice between aggressive surgery, minimally invasive ablation, or systemic medical therapy. This study synthesizes data from a 22-year institutional review and a systematic literature search to provide a preliminary framework for managing these complex cases.

Methodology

The researchers employed a dual-track approach:

  • Retrospective Clinical Review: Analysis of records for all patients treated for PC with liver metastases at the Peking Union Medical College Hospital (PUMCH) between 2000 and 2022. This institutional cohort included 3 patients (1.18% of their total 254 PC patients).
  • Systematic Literature Review: A search across Medline, Web of Science, and Embase (through August 2022) identified 11 additional eligible cases.

The total cohort of 14 patients was analyzed to correlate biochemical markers (PTH and serum calcium) with imaging modalities (CT, MRI, PET-CT) and pathological findings.

Key Insights and Clinical Course

Biochemical Indicators

Abnormally elevated PTH and serum calcium are the most reliable indicators of recurrence. In all 14 cases, patients exhibited borderline remission of hypercalcemia, signaling persistent disease. The median time from initial PC diagnosis to the discovery of liver metastases was 36 months (range: 1–122 months), emphasizing the need for long-term surveillance.

Clinical course of Patient 1 showing PTH and serum calcium fluctuations relative to surgical interventions.

Imaging and Metastatic Patterns

Abdominal CT scans were the most effective modality, detecting 71.4% of liver lesions. MRI provided valuable support, showing characteristic "halo ring-like" enhancement. However, PET-CT results were inconsistent, and the sensitivity of [18F]FDG-PET-CT for PC liver metastases remains questionable. Liver metastases in PC are often hematogenous and multifocal, frequently involving multiple liver segments simultaneously.

Treatment Outcomes

Local treatments, including surgical resection and radiofrequency ablation (RFA), led to immediate and significant reductions in serum calcium and PTH levels. This provides vital relief from hypercalcemia symptoms such as bone pain, kidney stones, and polyuria. Of the nine patients who underwent active intervention (surgery, RFA, or transcatheter arterial embolization), eight (88.9%) were alive at the time of follow-up, suggesting that aggressive local management is beneficial.

Clinical course of Patient 2 illustrating multiple surgeries and the corresponding biochemical response.

Conclusion and Future Directions

The primary limitation of this study is the small sample size (N=14), inherent to ultra-rare diseases. Future research should focus on evaluating newer PET tracers like [18F]FCH or [11C]choline for better localization of recurrences. Additionally, interdisciplinary prospective controlled studies are needed to establish formal guidelines and confirm the long-term efficacy of combined-modality treatments.

Summary updated

Abstract

PC is a rare malignant tumor prone to recurrence and metastasis, and postoperative reviews should be carried out routinely. Abnormally elevated parathyroid hormone (PTH) and serum calcium can indicate recurrence or metastasis. Enhanced CT and MRI can provide valuable support for the diagnosis of liver metastases, but whether [18F]FDG-PET-CT, [18F]FCH-PET-CT, or [11C]choline-PET-CT can be used as a diagnostic basis requires further study. Resection of liver metastases, segmental hepatectomy, or RFA can significantly improve patients' symptoms.
BibTeX
@inproceedings{su2022diagnosis,
  author = {Chaoyun Su and Junwei Zhang and Huayu Yang and Yiyao Xu and Xin Lü},
  title = {{Diagnosis and treatment of liver metastases of parathyroid carcinoma}},
  booktitle = {Frontiers in Endocrinology},
  year = {2022},
  doi = {10.3389/fendo.2022.982972},
}
Figure